Table 2 Clinical characteristics of recruited patients
Patients with fatigue (randomized) | Patients without fatigue (control) | p | |
|---|---|---|---|
Age (mean ± standard deviation) | 48.9 ± 9.6 | 55.7 ± 3.8 | 0,08 |
Race | |||
African-American | 26(81.3%) | 9 (81.8%) | 0.8 |
Caucasian | 2 (6.2%) | 2 (18.2%) | 0.8 |
Stage | |||
I | 5 (15.6%) | 3 (27.3%) | 0.33 |
II | 15 (46.9%) | 3 (27.3%) | 0.10 |
III | 12 (37.5%) | 6 (45.4%) | 0.40 |
Body Mass Index | 23.1 ± 2 | 22.3 ± 1,2 | p = 0.8 |
Histological Type | |||
Ductal Carcinoma | 28 (87.4%) | 11 (100%) | 0.6 |
Lobular Carcinoma | 2 (6.3%) | - | - |
Metaplastic Carcinoma | 2 (6.3%) | - | - |
Hormone Receptors/HER2 | |||
Hormone Receptor - positive, HER2 -positive | 9 (28.1%) | 3 (27.3%) | 0.99 |
Hormone Receptor - positive, HER2 - negative | 13 (40.7%) | 5 (45.4%) | 0.80 |
Hormone Receptor -negative, HER2 positive | 1 (3.1%) | 1 (9.1%) | 1 |
Triple-negative | 9 (28.1%) | 2 (18.2%) | 0.70 |
Type of Chemotherapy | |||
Adjuvant | 18 (56.2%) | 5 (45.5%) | 0.40 |
Neoadjuvant | 14 (43.8%) | 6 (54.5%) | 0.70 |
Comorbidities | |||
Lack of Comorbidities | 26 (81.3%) | 9 (81.8%) | 0.80 |
Arterial hypertension | 2 (6.2%) | 2 (18.2%) | 0.80 |
Diabetes mellitus | 4 (12.5%) | 0 | - |
Menopausal Status | |||
Premenopausal | 13 (40.6%) | 9 (81.8%) | 0.10 |
Postmenopausal | 19 (59.4%) | 2 (18.2%) | 0.20 |